CKD
2
Pipeline Programs
5
Companies
5
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
5 companies ranked by most advanced pipeline stage
Boehringer IngelheimINGELHEIM, Germany
1 program1
vicadrostat / empagliflozin combination 1Phase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
Renibus TherapeuticsVeverimer
Boehringer Ingelheimvicadrostat / empagliflozin combination 1
Fresenius KabiRenalive® LP, flavour Vanilla
Medical ComponentsLong term hemodialysis catheter
T-TherapeuticsFMD
Clinical Trials (5)
Total enrollment: 180 patients across 5 trials
A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis
Start: Jan 2026Est. completion: Jun 2027
Phase 3Recruiting
Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)
Start: Feb 2026Est. completion: Feb 2028100 patients
Phase 2Not Yet Recruiting
Suitability of Two Flavours of a High-energy, Low-protein Formula (Renalive® LP) in Chronic Kidney Disease Stage 3b-5 Outpatients in Taiwan
Start: May 2025Est. completion: Apr 202680 patients
N/ANot Yet Recruiting
Long Term Hemodialysis Catheters (LTHD) Post Market Clinical Follow up (PMCF)
Start: Mar 2022Est. completion: Mar 20230
N/AWithdrawn
Long Term Cardio-Vascular Risk Assessment in CKD and Kidney Transplanted Patients Following SARS-COV-2
Start: Jan 2021Est. completion: Mar 2024
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 180 patients
5 companies competing in this space